GSK Bio
NEWS
As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in.
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
It’s uncertain if the origins of COVID-19 will ever be determined, but the current top theories split about evenly between a lab leak from the Wuhan Institute of Virology and a natural evolution from bats to animals to humans at a Wuhan “wet market.”
As GSK moves into the new year, Chief Executive Officer Emma Walmsley predicted 2022 will be a “landmark year” for the company.
Bayer isn’t the only company to announce changes to its leadership team this morning. Editas, Biogen, Takeda, Merck and Vedere Bio also announced leadership changes.
This week, Gilead Sciences took a $1.25 billion hit after reaching a settlement with ViiV Healthcare on a patent dispute involving the HIV drug dolutegravir.
The company initiated the use of splenic nerve simulation last month as part of a small clinical trial at the NHS Greater Glasgow & Clyde Health Board in Scotland.
TScan Therapeutics, Lyell, SQZ Biotech and others secured clearance from the U.S. Food and Drug Administration for their Investigational New Drug Application.
Unilever announced Wednesday that it will not increase its bid over the recently proposed £50 billion (about $68 billion) to ensure that the acquisitions create value for its shareholders.
JOBS
IN THE PRESS